• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受超声心动图检查时使用与未使用超声造影剂的住院患者的急性死亡率:18671项连续研究的结果

Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies.

作者信息

Kusnetzky Lisa L, Khalid Adnan, Khumri Taiyeb M, Moe Tabitha G, Jones Philip G, Main Michael L

机构信息

Saint Luke's Mid America Heart Institute, Kansas City, Missouri 64111, USA.

出版信息

J Am Coll Cardiol. 2008 Apr 29;51(17):1704-6. doi: 10.1016/j.jacc.2008.03.006. Epub 2008 Apr 9.

DOI:10.1016/j.jacc.2008.03.006
PMID:18436124
Abstract

OBJECTIVES

We sought to define acute mortality in hospitalized patients undergoing clinically indicated echocardiography with and without use of an ultrasound contrast agent.

BACKGROUND

The U.S. Food and Drug Administration recently issued a boxed warning and new contraindications for the perflutren-containing ultrasound contrast agents following post-marketing reports of 4 patient deaths that were temporally related to Definity (Bristol-Myers Squibb Medical Imaging, Billerica, Massachusetts) administration. To appreciate the incremental risk of any medical procedure, the ambient risk of untoward outcome in the population in question must first be defined. There are no published data on short-term major adverse cardiac events in hospitalized patients undergoing echocardiography, either with or without administration of an ultrasound contrast agent.

METHODS

A retrospective analysis of hospitalized patients undergoing clinically indicated echocardiography between January 2005 and October 2007, within Saint Luke's Health System, Kansas City, Missouri, was performed. Studies were separated into 2 groups, those performed without contrast enhancement (n = 12,475) and those performed with Definity (n = 6,196). Vital status within 24 h of the echocardiographic study was available for all patients using a combination of the Social Security Death Master File and Saint Luke's Health System medical records. Incidence of death within 24 h was compared by chi-square test between Definity and unenhanced procedures.

RESULTS

Of the 18,671 patient events, 72 patients died within 24 h. Of those that underwent unenhanced echocardiography, 46 died within 24 h (0.37%). Of patients receiving Definity during the echocardiogram, 26 died within 24 h (0.42%). There was no statistical difference between these 2 groups (p = 0.60). No patient died within 1 h of the echocardiographic study. In a random sampling from the unenhanced (n = 201) and Definity groups (n = 202), patients who underwent Definity-enhanced echocardiography exhibited higher clinical acuity, and more significant comorbidities.

CONCLUSIONS

Approximately 0.4% of hospitalized patients die within 24 h of echocardiography. There is no increased mortality risk associated with Definity-enhanced examinations, despite evidence for higher clinical acuity and more comorbid conditions in patients undergoing contrast studies.

摘要

目的

我们试图确定在接受临床指征超声心动图检查时使用和不使用超声造影剂的住院患者的急性死亡率。

背景

美国食品药品监督管理局(FDA)在收到4例与Definity(百时美施贵宝医学影像公司,马萨诸塞州比勒里卡)给药时间相关的患者死亡的上市后报告后,最近发布了关于含全氟丙烷超声造影剂的盒装警告和新的禁忌证。为了了解任何医疗程序的额外风险,必须首先确定相关人群中不良后果的背景风险。关于接受超声心动图检查的住院患者,无论是否使用超声造影剂,短期主要不良心脏事件均无发表的数据。

方法

对2005年1月至2007年10月在密苏里州堪萨斯城圣卢克医疗系统内接受临床指征超声心动图检查的住院患者进行回顾性分析。研究分为两组,未进行造影增强的患者(n = 12,475)和使用Definity的患者(n = 6,196)。使用社会保障死亡主文件和圣卢克医疗系统的医疗记录相结合的方式,可获得所有患者在超声心动图检查后24小时内的生命状态。通过卡方检验比较Definity组和未增强检查组24小时内的死亡率。

结果

在18,671例患者事件中,72例在24小时内死亡。在接受未增强超声心动图检查的患者中,46例在24小时内死亡(0.37%)。在超声心动图检查期间接受Definity的患者中,26例在24小时内死亡(0.42%)。这两组之间无统计学差异(p = 0.60)。在超声心动图检查后1小时内无患者死亡。从未增强组(n = 201)和Definity组(n = 202)中随机抽样,接受Definity增强超声心动图检查的患者表现出更高的临床敏锐度和更严重的合并症。

结论

约0.4%的住院患者在超声心动图检查后24小时内死亡。尽管有证据表明接受造影检查的患者临床敏锐度更高且合并症更多,但Definity增强检查并未增加死亡风险。

相似文献

1
Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies.接受超声心动图检查时使用与未使用超声造影剂的住院患者的急性死亡率:18671项连续研究的结果
J Am Coll Cardiol. 2008 Apr 29;51(17):1704-6. doi: 10.1016/j.jacc.2008.03.006. Epub 2008 Apr 9.
2
Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients).接受超声心动图检查时使用和未使用超声造影剂的住院患者的急性死亡率(4300966例连续患者的多中心登记结果)
Am J Cardiol. 2008 Dec 15;102(12):1742-6. doi: 10.1016/j.amjcard.2008.08.019. Epub 2008 Oct 23.
3
A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent.回顾性比较行超声心动图检查与不行超声心动图检查的危重症住院患者的死亡率。
JACC Cardiovasc Imaging. 2010 Jun;3(6):578-85. doi: 10.1016/j.jcmg.2010.04.006.
4
Administration of perflutren contrast agents during transthoracic echocardiography is not associated with a significant increase in acute mortality risk.在经胸超声心动图检查期间给予全氟三丙胺造影剂与急性死亡风险的显著增加无关。
Cardiology. 2012;122(2):119-25. doi: 10.1159/000338731. Epub 2012 Jul 18.
5
Safety of contrast-enhanced echocardiography within 24 h after acute myocardial infarction.急性心肌梗死后24小时内超声心动图造影的安全性。
Eur J Echocardiogr. 2008 Nov;9(6):816-8. doi: 10.1093/ejechocard/jen167. Epub 2008 Jul 16.
6
Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience.用于静息和负荷超声心动图的市售超声造影剂的安全性和有效性:一项多中心经验
J Am Coll Cardiol. 2009 Jan 6;53(1):32-8. doi: 10.1016/j.jacc.2008.08.066.
7
Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent.危重症患者行超声心动图检查(有或无超声造影剂)的急性死亡率。
JACC Cardiovasc Imaging. 2014 Jan;7(1):40-8. doi: 10.1016/j.jcmg.2013.08.012. Epub 2013 Nov 27.
8
CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice.CaRES(对比超声心动图安全性监测登记研究):一项前瞻性多中心研究,旨在评估超声造影剂声诺维在临床实践中的安全性。
J Am Soc Echocardiogr. 2012 Jul;25(7):790-5. doi: 10.1016/j.echo.2012.04.002. Epub 2012 May 3.
9
Ultrasound contrast agents: balancing safety versus efficacy.超声造影剂:平衡安全性与有效性
Expert Opin Drug Saf. 2009 Jan;8(1):49-56. doi: 10.1517/14740330802658581.
10
Safety profile of ultrasound enhancing agents in echocardiography.超声心动图中超声增强剂的安全性概况。
Echocardiography. 2019 Jun;36(6):1041-1044. doi: 10.1111/echo.14344. Epub 2019 Apr 30.

引用本文的文献

1
Standardizing Safety Practices for Contrast Enhanced Ultrasound in Radiology.规范放射学中超声造影的安全操作规范
J Ultrasound Med. 2025 Jun 24. doi: 10.1002/jum.16752.
2
Contemporary Safety of Ultrasound Enhancing Agents in a Nationwide Analysis.全国性分析中超声增强剂的当代安全性
J Am Heart Assoc. 2025 May 20;14(10):e039480. doi: 10.1161/JAHA.124.039480. Epub 2025 May 14.
3
Multi-societal expert consensus statement on the safe administration of ultrasound contrast agents.关于超声造影剂安全使用的多学会专家共识声明。
Echo Res Pract. 2025 Feb 21;12(1):4. doi: 10.1186/s44156-024-00068-7.
4
Microbubble Enhanced Echocardiography in Current Cardiology Practice.当前心脏病学实践中的微泡增强超声心动图
Rev Cardiovasc Med. 2022 May 31;23(6):202. doi: 10.31083/j.rcm2306202. eCollection 2022 Jun.
5
Ultrasonographic assessment of renal microcirculation is a new vision for the treatment of intensive care unit associated acute kidney injury.肾脏微循环的超声评估是治疗重症监护病房相关急性肾损伤的新视角。
Eur J Med Res. 2024 Feb 10;29(1):115. doi: 10.1186/s40001-024-01704-y.
6
Efficacy and safety of use of ultrasound enhancing agent in patients hospitalized with COVID-19.在 COVID-19 住院患者中使用超声增强剂的疗效和安全性。
Int J Cardiovasc Imaging. 2024 Mar;40(3):625-632. doi: 10.1007/s10554-023-03032-4. Epub 2023 Dec 14.
7
Safety of Lumason® (SonoVue®) in special populations and critically ill patients.Lumason®(声诺维®)在特殊人群和重症患者中的安全性。
Front Cardiovasc Med. 2023 Aug 2;10:1225654. doi: 10.3389/fcvm.2023.1225654. eCollection 2023.
8
CEUS cardiac exam protocols International Contrast Ultrasound Society (ICUS) recommendations.CEUS心脏检查方案 国际超声造影学会(ICUS)建议
Echo Res Pract. 2022 Aug 23;9(1):7. doi: 10.1186/s44156-022-00008-3.
9
Initial experience with Duplex scan combined with contrast-enhanced ultrasound for follow-up of endovascular abdominal aortic aneurysm repair.双功超声联合超声造影在血管内腹主动脉瘤修复术后随访中的初步经验。
J Vasc Bras. 2021 Nov 1;20:e20200093. doi: 10.1590/1677-5449.200093. eCollection 2021.
10
Contrast Ultrasound, Sonothrombolysis and Sonoperfusion in Cardiovascular Disease: Shifting to Theragnostic Clinical Trials.心血管疾病中的超声造影、声溶栓和声灌注:向治疗诊断临床试验的转变。
JACC Cardiovasc Imaging. 2022 Feb;15(2):345-360. doi: 10.1016/j.jcmg.2021.07.028. Epub 2021 Oct 13.